TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03509662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One group receives a placebo.
Study: NCT02063308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxaloacetate (OAA)
Study: NCT01702077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study: NCT01209546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flutter group
Description: Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEP group
Description: Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group Sham
Description: Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
Study: NCT00437346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized and comprehensive information
Description: Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanzo Melt
Description: 30mg, od, 1/2 h before meal
Study: NCT01702077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham feedback

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham feedback
Study: NCT01345526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reconval K1 Cream

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reconval Cream
Study: NCT02393118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort V200 Device
Description: Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
Study: NCT00437346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanzo Melt
Description: 30mg, od, 1/2 h before meal
Study: NCT02116543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01930045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (ISENTRESS™)
Description: Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1
Study: NCT02656758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive Executive function training
Description: Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: intensive Executive function training
Description: Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
Study: NCT04233359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic thoracoscopy
Description: Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided pleural biopsy
Description: In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
Study: NCT04064320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lullaby intervention
Description: Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
Study: NCT03888391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TNS
Study: NCT04313361

Intervention type: OTHER
Intervention: No intervention
Description: No drug will be administered as part of this study.
Study: NCT03790462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected.
Study: NCT01930045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1
Study: NCT03790462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected.
Study: NCT03247660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM training
Description: See information included in arm/group descriptions.
Study: NCT01930045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAALOX (MAL)
Description: MAL (or generic equivalent) 20 mL oral single dose on Day 1
Study: NCT04397198

Intervention type: DIAGNOSTIC_TEST
Intervention: Speckle Tracking echocardiography
Description: Diagnostic tests:~Speckle Tracking echocardiography with analyzing the myocardial strain, myocardial velocities, 128-multislice CCTA with the evaluation of the Calcium Scoring (total and local) , identifying the coronary stenosis, evaluation of the plaque vulnerability degree, assess polar maps of the myocardium.~MRI for the evaluation of the percentage of myocardial scar, also the percentage of the viable myocardial tissue using contrast late enhancement sequences, measuring myocardial fibrosis using Q-mass software.~Diagnostic tests:~Laboratory assessment for the evaluation of the level of hs-CRP and myocardial necrosis biomarkers
Study: NCT00829348

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: 60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
Study: NCT03247660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HE
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HE
Description: See information included in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational strategy
Description: See information included in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational strategy
Description: See information included in arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational strategy
Description: See information included in arm/group descriptions.
Study: NCT00829348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Description: 60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
Study: NCT05590650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SZKJT(San-Zhong-Kui-Jian-Tang)
Description: The SZKJT samples were made and packed by Kaiser Pharmaceutical Co. Ltd. with lot number of 2019023247.
Study: NCT05025579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done.
Study: NCT00748553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (Vidaza)
Description: 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
Study: NCT03060642

Intervention type: DEVICE
Intervention: Tethered capsule sponge
Description: Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.

Intervention type: DEVICE
Intervention: Tethered capsule sponge
Description: Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
Study: NCT00748553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (Abraxane)
Description: 100mg/m2 weekly for 3 weeks of each 4-week cycle
Study: NCT00585923

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed hole C-Tek™ Plate
Description: Fixed hole C-Tek™ Plate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Slotted hole C-Tek™ Plate
Description: Slotted hole C-Tek™ Plate
Study: NCT05827484

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous platelets rich plasma
Description: 30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Autologous platelets rich plasma + oral LOSARTAN administration
Description: in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
Study: NCT04787952

Intervention type: OTHER
Intervention: cold expossure
Description: subjects were exposed for the cold, to activate and diagnose potential brown tissue activity

Intervention type: OTHER
Intervention: cold expossure
Description: subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
Study: NCT04423159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OCV Vaccine
Description: 2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
Study: NCT02150772

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shear Wave Elastography (SWE)
Study: NCT01754818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 50mg
Study: NCT03060642

Intervention type: DEVICE
Intervention: Electronic nose device
Description: Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
Study: NCT01754818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02723929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active low-intensity transcranial electrical stimulation/active transcranial ultrasound
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
Study: NCT02749578

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin

Intervention type: DRUG
Group type: OTHER
Intervention: MGL-3196
Study: NCT00831415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release tablets
Description: 25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
Study: NCT02329613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard evening meals.
Description: Patients will receive usual evening meals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved evening meal
Description: Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
Study: NCT05502458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desﬂurane
Description: Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h. In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane. The analgesic and muscle relaxant regimens were the same in both groups except for sedative drugs. All patients were treated with no medication before operation, and the operation was completed under endotracheal intubation and general anesthesia. The amount of propofol or desflurane was adjusted according to BIS or MAC values and hemodynamic changes during operation. Add 10mg of rocuronium every half hour. Vasoactive drugs can be used to maintain hemodynamic stability during the operation, and corresponding records should be made

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.
Study: NCT01461655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed topical retinoid
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marketed topical NSAID
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: once daily application, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: marketed topical retinoid
Description: once daily application, 4 weeks
Study: NCT03804918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VitalTips mobile application
Description: VitalTips is a mobile learning application with learning on breaking bad news. Participants were expected to spend at least three hours using the mobile learning resource, ensuring that the time did not impact on their clinical and academic commitments.
Study: NCT00779545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
Study: NCT03023280

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Study: NCT03208101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP-HepB-IPV-Hib vaccine
Description: Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP-HepB-Hib vaccine & IPV
Description: Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)